Literature DB >> 22527850

Chronic myeloid leukaemia and human immunodeficiency virus (HIV) infection.

Michael J Webb1, Claire L Barrett, Christel Pretorius, Magdalena F van Jaarsveld, Vernon J Louw.   

Abstract

The occurrence of chronic myeloid leukaemia (CML) in patients infected with the human immunodeficiency virus (HIV) has rarely been reported in the literature. In this report, we describe the experience of a single centre in the management of 10 such patients, including demographic information, disease characteristics and response to therapy. We had a black female predominance in our series, with only a minority of patients achieving a complete cytogenetic response. The main reason for this appears to be compliance, which was influenced by distance to the treating centre. The side-effect profile was similar to that expected, with the exception of one patient who developed a drug rash with eosinophilia and systemic symptoms. Although CML patients co-morbid for HIV face certain unique challenges when compared to non-infected patients, their long-term outcome can be positive when appropriately managed.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22527850     DOI: 10.1007/s12185-012-1073-2

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.319


  45 in total

1.  A systematic review of the associations between dose regimens and medication compliance.

Authors:  A J Claxton; J Cramer; C Pierce
Journal:  Clin Ther       Date:  2001-08       Impact factor: 3.393

2.  Reduction of immunoglobulin levels during imatinib therapy of chronic myeloid leukemia.

Authors:  Giulia Cervetti; Giovanni Carulli; Sara Galimberti; Antonio Azzarà; Elisa Cannizzo; Gabriele Buda; Enrico Orciuolo; Mario Petrini
Journal:  Leuk Res       Date:  2007-03-29       Impact factor: 3.156

3.  Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score.

Authors:  Joerg Hasford; Michele Baccarani; Verena Hoffmann; Joelle Guilhot; Susanne Saussele; Gianantonio Rosti; François Guilhot; Kimmo Porkka; Gert Ossenkoppele; Doris Lindoerfer; Bengt Simonsson; Markus Pfirrmann; Rudiger Hehlmann
Journal:  Blood       Date:  2011-05-02       Impact factor: 22.113

4.  Nonadherence to imatinib adversely affects event free survival in chronic phase chronic myeloid leukemia.

Authors:  Prasanth Ganesan; Tenali Gnana Sagar; Biswajit Dubashi; Rejiv Rajendranath; Krishnarathinam Kannan; Sanju Cyriac; Manjunath Nandennavar
Journal:  Am J Hematol       Date:  2011-04-27       Impact factor: 10.047

5.  Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study.

Authors:  Jonathan A C Sterne; Miguel A Hernán; Bruno Ledergerber; Kate Tilling; Rainer Weber; Pedram Sendi; Martin Rickenbach; James M Robins; Matthias Egger
Journal:  Lancet       Date:  2005 Jul 30-Aug 5       Impact factor: 79.321

6.  Chronic myeloid leukemia and HIV-infection.

Authors:  Robert Schlaberg; Julie G Fisher; Michael J Flamm; Vundavalli V Murty; Govind Bhagat; Bachir Alobeid
Journal:  Leuk Lymphoma       Date:  2008-06

7.  Clinical trials underestimate the age of chronic myeloid leukemia (CML) patients. Incidence and median age of Ph/BCR-ABL-positive CML and other chronic myeloproliferative disorders in a representative area in Germany.

Authors:  M Rohrbacher; U Berger; A Hochhaus; G Metzgeroth; K Adam; T Lahaye; S Saussele; M C Müller; J Hasford; H Heimpel; R Hehlmann
Journal:  Leukemia       Date:  2008-09-11       Impact factor: 11.528

Review 8.  Drug hypersensitivity in HIV.

Authors:  Elizabeth Phillips; Simon Mallal
Journal:  Curr Opin Allergy Clin Immunol       Date:  2007-08

9.  Changes of immunological profiles in patients with chronic myeloid leukemia in the course of treatment.

Authors:  Zuzana Humlová; Hana Klamová; Ivana Janatková; Karin Malíčková; Petra Králíková; Ivan Sterzl; Zdeněk Roth; Eva Hamšíková; Vladimír Vonka
Journal:  Clin Dev Immunol       Date:  2010-12-12

10.  Nilotinib hampers the proliferation and function of CD8+ T lymphocytes through inhibition of T cell receptor signalling.

Authors:  J Chen; A Schmitt; B Chen; M Rojewski; V Rübeler; F Fei; Y Yu; X Yu; M Ringhoffer; S von Harsdorf; J Greiner; M Götzz; P Guillaume; H Döhner; D Bunjes; M Schmitt
Journal:  J Cell Mol Med       Date:  2008-01-11       Impact factor: 5.310

View more
  3 in total

1.  Plasma cell leukaemia and HIV co-infection: profile of patients and experience at Universitas Academic Hospital in Bloemfontein, South Africa.

Authors:  Mubarak Ariyo Bidmos; Sunette Joubert; Magdalena F P C van Jaarsveld; Vernon J Louw
Journal:  Int J Hematol       Date:  2013-11-21       Impact factor: 2.490

2.  Human immunodeficiency virus Infection in a patient of chronic myelogenous leukemia.

Authors:  Vijay B Tuljapurkar; Uday A Phatak
Journal:  Indian J Med Paediatr Oncol       Date:  2013-10

Review 3.  Coinfections and comorbidities in African health systems: At the interface of infectious and noninfectious diseases.

Authors:  Derick Nii Mensah Osakunor; David Moinina Sengeh; Francisca Mutapi
Journal:  PLoS Negl Trop Dis       Date:  2018-09-20
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.